Emapalumab - Swedish Orphan Biovitrum
Alternative Names: emapalumab-lzsg; Gamifant; NI-0501Latest Information Update: 30 May 2024
At a glance
- Originator NovImmune SA
- Developer Institut Merieux; Swedish Orphan Biovitrum
- Class Monoclonal antibodies
- Mechanism of Action Interferon gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophagocytic lymphohistiocytosis
- Phase II/III COVID 2019 infections
- Phase II Transplant rejection
- No development reported Unspecified
Most Recent Events
- 24 May 2024 Emapalumab - Swedish Orphan Biovitrum receives Fast Track designation for Haemophagocytic lymphohistiocytosis in USA (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Japan (IV, Infusion)
- 31 Dec 2023 Launched for Haemophagocytic lymphohistiocytosis in United Arab Emirates (IV) prior to December 2023